The Orient Securities Research Report pointed out that Hisco's domestic and overseas dual-drive performance is growing rapidly. Net profit for the first three quarters of 2026 was 1,376 billion yuan, +314.02% year-on-year. It continues to expand major indications, and the market potential has steadily increased. International licensing exploded, and the platform's R&D capabilities were well recognized by MNC. In terms of early research, the company has established high-barrier technology platforms such as macromolecules, targeted protein degradation, blood-brain barrier penetration, and inhalation formulations, expanding from the original small molecules to biopharmaceuticals and polypeptide drugs covering antibodies, antibody conjugates, and recombinant proteins. According to the draft equity incentive plan announced in August of this year, 5 to 6 new INDs will be accepted every year for the next 3 years, and it is expected that overseas will be normalized. According to the company's 2026 three-quarter report, the company's 2026-2028 revenue and gross margin forecast was raised, and the cost rate forecast for the same period was lowered. Considering that many innovative drug pipelines are in the clinical stage, the DCF valuation method was adopted, and the corresponding target price was 81.81 yuan, maintaining the “buy” rating.

Zhitongcaijing · 2d ago
The Orient Securities Research Report pointed out that Hisco's domestic and overseas dual-drive performance is growing rapidly. Net profit for the first three quarters of 2026 was 1,376 billion yuan, +314.02% year-on-year. It continues to expand major indications, and the market potential has steadily increased. International licensing exploded, and the platform's R&D capabilities were well recognized by MNC. In terms of early research, the company has established high-barrier technology platforms such as macromolecules, targeted protein degradation, blood-brain barrier penetration, and inhalation formulations, expanding from the original small molecules to biopharmaceuticals and polypeptide drugs covering antibodies, antibody conjugates, and recombinant proteins. According to the draft equity incentive plan announced in August of this year, 5 to 6 new INDs will be accepted every year for the next 3 years, and it is expected that overseas will be normalized. According to the company's 2026 three-quarter report, the company's 2026-2028 revenue and gross margin forecast was raised, and the cost rate forecast for the same period was lowered. Considering that many innovative drug pipelines are in the clinical stage, the DCF valuation method was adopted, and the corresponding target price was 81.81 yuan, maintaining the “buy” rating.